M&A Is Back. 4 Stocks That Could Be Targets
By Jacob Sonenshine Mergers are back -- and that means opportunity for small-cap investors. Small-caps don't have a lot going for them. The Russell 2000 index has gained 0.2% this year, lagging the
Check Out What Whales Are Doing With AMGN
Whales with a lot of money to spend have taken a noticeably bearish stance on Amgen.Looking at options history for Amgen (NASDAQ:AMGN) we detected 67 trades.If we consider the specifics of each trade,
Here Is What to Know Beyond Why Amgen Inc. (AMGN) Is a Trending Stock
USA faces the most severe drug shortage in a decade, with low stock price drugs and weight loss drugs becoming "disaster zones".
Last year, the USA experienced the most serious drug shortage crisis in a decade.
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Raises Target Price to $332
RBC Capital analyst Gregory Renza maintains $Amgen(AMGN.US)$ with a buy rating, and adjusts the target price from $328 to $332.According to TipRanks data, the analyst has a success rate of 45.4% and a
Amgen's Dezmaab injection has been approved for a new indication in China.
DiShuSingle Antibody Injection has been approved for three indications in China.
FDA Grants Expanded Approval for Amgen's Blincyto in ALL
Amgen Gets FDA Approval to Treat Aggressive Leukemia Type With Blincyto
By Sabela Ojea Amgen said the Food and Drug Administration has approved Blincyto to treat an aggressive type of blood cancer. The biotechnology company on Friday said the approval is aimed at adult
Express News | Amgen Announces FDA Approval Of BLINCYTO In CD19-Positive Philadelphia Chromosome-Negative B-ALL
Express News | Amgen- Blincyto Added to Multiphase Consolidation Chemotherapy Reduced Risk of Death by 58% Showing Superior Overall Survival Vs Chemotherapy Alone
Express News | FDA Approves Blincyto® (Blinatumomab) in Cd19-Positive Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (B-All) in the Consolidation Phase
The Whole Dow Has Been a Dog. Don't Expect the Market to Throw It a Bone.
Blame the recent slide of the Dow Jones Industrial Average on the fact that it is price-weighted, and more exposed to lagging cyclicals than red-hot techs.
Gilead Stock Gains. It's Trying to Get Into the Obesity Drug Game.
A success would be a gamechanger for the biotech company known for its HIV treatments.
Sector Update: Health Care Stocks Softer Friday Afternoon
Health care stocks eased Friday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both shedding about 0.2%. The iShares Biotechnology ETF (IBB) declined 0.8%
Amgen Is Maintained at Outperform by RBC Capital
Amgen Is Maintained at Outperform by RBC Capital
Express News | RBC Capital Maintains Outperform on Amgen, Raises Price Target to $332
Amgen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/14/2024 11.78% RBC Capital $328 → $332 Maintains Outperform 05/09/2024 -20.88% Mizuho $223 → $235 Maint
Express News | Amgen Inc : RBC Raises Target Price to $332 From $328
Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
JPMorgan to Wager on Weight-Loss Craze With $500 Million Fund
JPMorgan Chase & Co.’s asset-management arm raised more than $500 million for a biotech venture-capital fund that will bet on the hottest corner of health care: weight-loss drugs
No Data